The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics.

The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics.

We have investigated the relation between nocturnal insulin requirements and nocturnal growth hormone (GH) release in 26 diabetic adolescents at various puberty stages and have examined the effect of nocturnal GH suppression on pre-breakfast insulin requirement. In all the studies, euglycaemia was m...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Edge, J, Matthews, DR, Dunger, D
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	1990

Παρόμοια τεκμήρια

Increased overnight growth hormone concentrations in diabetic compared with normal adolescents.
ανά: Edge, J, κ.ά.
Έκδοση: (1990)

Evidence for a role for insulin and growth hormone in overnight regulation of 3-hydroxybutyrate in normal and diabetic adolescents.
ανά: Edge, J, κ.ά.
Έκδοση: (1993)

Failure of current insulin regimes to meet the overnight requirements of adolescents with insulin-dependent diabetes.
ανά: Edge, J, κ.ά.
Έκδοση: (1990)

Spontaneous growth hormone (GH) pulsatility is the major determinant of GH release after thyrotrophin-releasing hormone in adolescent diabetics.
ανά: Edge, J, κ.ά.
Έκδοση: (1989)

Evidence for temporal coupling of growth hormone, prolactin, LH and FSH pulsatility overnight during normal puberty.
ανά: Dunger, D, κ.ά.
Έκδοση: (1991)

Impact of increased growth hormone secretion on carbohydrate metabolism in adolescents with diabetes.
ανά: Dunger, D, κ.ά.
Έκδοση: (1991)

The growth hormone releasing hormone (GHRH) response to a mixed meal is blunted in young adults with insulin-dependent diabetes mellitus whereas the somatostatin response is normal.
ανά: Foot, AB, κ.ά.
Έκδοση: (1990)

An unbiased glucose clamp method using a variable insulin infusion: its application in diabetic adolescents.
ανά: Matthews, DR, κ.ά.
Έκδοση: (1990)

The frequency and amplitude of growth hormone secretory episodes as determined by deconvolution analysis are increased in adolescents with insulin dependent diabetes mellitus and are unaffected by short-term euglycaemia.
ανά: Pal, B, κ.ά.
Έκδοση: (1993)

The effects of recombinant human insulin-like growth factor I on growth hormone secretion in adolescents with insulin dependent diabetes mellitus.
ανά: Cheetham, T, κ.ά.
Έκδοση: (1994)

The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity.
ανά: Massoud, A, κ.ά.
Έκδοση: (1996)

The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with type 1 (insulin-dependent) diabetes mellitus.
ανά: Cheetham, T, κ.ά.
Έκδοση: (1993)

Retrospective trial of long acting analogues detemir and degludec usage in children and adolescents to overcome glucose variability caused by dawn phenomenon and reverse dawn phenomenon
ανά: A. V. Vitebskaya, κ.ά.
Έκδοση: (2021-11-01)

Half-life of exogenous growth hormone following suppression of endogenous growth hormone secretion with somatostatin in type I (insulin-dependent) diabetes mellitus.
ανά: Mullis, P, κ.ά.
Έκδοση: (1992)

The relationship between overnight GH levels and insulin concentrations in adolescents with insulin-dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor I (rhIGF-I).
ανά: Cheetham, T, κ.ά.
Έκδοση: (1997)

Growth Hormone-Releasing Hormone in Diabetes
ανά: Leonid Evsey Fridlyand, κ.ά.
Έκδοση: (2016-10-01)

Contrasting metabolic effects of continuous and pulsatile growth hormone administration in young adults with type 1 (insulin-dependent) diabetes mellitus.
ανά: Pal, B, κ.ά.
Έκδοση: (1992)

Does recombinant insulin-like growth factor I have a role in the treatment of insulin-dependent diabetes mellitus during adolescence?
ανά: Dunger, D, κ.ά.
Έκδοση: (1993)

Does recombinant insulin-like growth factor I have a role in the treatment of insulin-dependent diabetes mellitus during adolescence?
ανά: Dunger, D, κ.ά.
Έκδοση: (1993)

The correlation of dawn phenomenon with glycemic variability parameters in type 2 diabetes mellitus
ανά: Roman Gabriela, κ.ά.
Έκδοση: (2016-03-01)

The effect of moderate weight loss on overnight growth hormone and cortisol secretion in healthy female volunteers.
ανά: Anderson, I, κ.ά.
Έκδοση: (1989)

THE OVERNIGHT CONSULTANT /
ανά: Lewin, Marsha D. 242587
Έκδοση: (1995)

Increasing urine albumin excretion is associated with growth hormone hypersecretion and reduced clearance of insulin in adolescents and young adults with type 1 diabetes: the Oxford Regional Prospective Study.
ανά: Amin, R, κ.ά.
Έκδοση: (2005)

The pituitary gland is capable of responding to two successive doses of growth hormone releasing hormone (GHRH)
ανά: Suri, D, κ.ά.
Έκδοση: (1991)

The interaction of growth hormone releasing hormone and somatostatin in the generation of a GH pulse in man.
ανά: Hindmarsh, P, κ.ά.
Έκδοση: (1991)

Growth-hormone-releasing factor in growth hormone deficiency: demonstration of a hypothalamic defect in growth hormone release.
ανά: Grossman, A, κ.ά.
Έκδοση: (1983)

Growth hormone releasing hormone.
ανά: Grossman, A, κ.ά.
Έκδοση: (1986)

Continuous subcutaneous growth hormone releasing factor analogue augments growth hormone secretion in normal male subjects with no desensitization of the somatotroph.
ανά: Brain, C, κ.ά.
Έκδοση: (1988)

Self-Monitoring of Blood Glucose to Assess Dawn Phenomenon in Chinese People with Type 2 Diabetes Mellitus
ανά: Wen Wu, κ.ά.
Έκδοση: (2017-01-01)

THE CHARACTERISTICS OF GROWTH-HORMONE (GH) PULSATILITY IN NEONATES
ανά: Adcock, C, κ.ά.
Έκδοση: (1994)

The effect of prolonged fasting on levels of growth hormone-binding protein and free growth hormone.
ανά: Salgin, B, κ.ά.
Έκδοση: (2012)

The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin(1-14)(SS) in growth hormone (GH) pulse generation: studies in normal and post cranial irradiated individuals.
ανά: Achermann, J, κ.ά.
Έκδοση: (1999)

The effect of growth hormone secretagogues on the release of growth hormone-releasing hormone, somatostatin, vasopressin, and corticotrophin-releasing hormone from the rat hypothalamus in vitro
ανά: Korbonits, M, κ.ά.
Έκδοση: (1998)

Treatment of growth-hormone deficiency with growth-hormone-releasing hormone.
ανά: Ross, R, κ.ά.
Έκδοση: (1987)

The interaction of growth hormone releasing hormone with other hypothalamic hormones on the release of anterior pituitary hormones.
ανά: Looij, B, κ.ά.
Έκδοση: (1986)

A probabilistic computation framework to estimate the dawn phenomenon in type 2 diabetes using continuous glucose monitoring
ανά: Souptik Barua, κ.ά.
Έκδοση: (2024-02-01)

The effect of changing somatostatin tone on the pituitary growth hormone and thyroid-stimulating hormone responses to their respective releasing factor stimuli.
ανά: Spoudeas, H, κ.ά.
Έκδοση: (1992)

Patient and provider perceptions of care for diabetes: results of the cross-national DAWN Study.
ανά: Peyrot, M, κ.ά.
Έκδοση: (2006)

GROWTH HORMONE-RELEASING HORMONE-TREATMENT OF GROWTH-HORMONE DEFICIENT CHILDREN
ανά: Ross, R, κ.ά.
Έκδοση: (1986)

Phenomenon of the “dawn attacks operation” as a money politics practices in Indonesian election
ανά: Yusa Djuyandi, κ.ά.
Έκδοση: (2024-08-01)